Comparative Pharmacology
Head-to-head clinical analysis: MAXITROL versus NEO POLYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXITROL versus NEO POLYCIN.
MAXITROL vs NEO-POLYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Maxitrol is a combination of dexamethasone (corticosteroid), neomycin (aminoglycoside antibiotic), and polymyxin B (polymyxin antibiotic). Dexamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Neomycin binds to bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis. Polymyxin B is a polypeptide antibiotic that disrupts bacterial cell membrane permeability by interacting with phospholipids. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
1-2 drops or 0.5-1 inch strip of ointment into the conjunctival sac every 4-6 hours; in severe cases, every 2-4 hours. Frequency may be reduced after improvement.
Apply a thin layer to the affected area 3 to 4 times daily. Use a unit-dose ointment or eye drops: 1 to 2 drops in the affected eye(s) every 4 to 6 hours, or more frequently as needed.
None Documented
None Documented
Neomycin: 2–3 h (topical) but prolonged in renal impairment. Polymyxin B: 6–7 h (topical). Dexamethasone: 3–4 h (topical). Clinical: systemic absorption minimal with intact epithelium; half-life may be prolonged with corneal abrasion or inflammation.
Neomycin: 2-3 hours in patients with normal renal function; prolonged to 12-24 hours in renal impairment. Polymyxin B: 6-8 hours. Bacitracin: 1.5 hours (if absorbed); typically not systemically available.
Renal: neomycin 30–50%; polymyxin B <1%; dexamethasone <1%. Fecal: neomycin >50% (unabsorbed); polymyxin B >99% (unabsorbed); dexamethasone <5%. Biliary: negligible for all components.
Neomycin: ~30-50% of absorbed dose excreted renally as unchanged drug; unabsorbed drug eliminated fecally. Polymyxin B: minimal renal excretion (<1% of dose); primarily eliminated via non-renal routes, possibly biliary or metabolic. Bacitracin: negligible renal excretion after topical use; systemic absorption minimal.
Category C
Category C
Ophthalmic Corticosteroid/Antibiotic Combination
Antibiotic Combination